Pharmaceutical manufacturing currently anchors the market, accounting for 62% of global revenue. The solvent remains a linchpin in active pharmaceutical ingredient synthesis and high-performance liquid chromatography. As global laboratories and biotech firms push for greater precision in drug discovery and vaccine production, the reliance on high-purity acetonitrile continues to scale accordingly.

Beyond medicine, the energy transition is reshaping production priorities. Manufacturers are increasingly integrating acetonitrile into electrolyte formulations for lithium-ion batteries, citing its chemical stability and low moisture content as critical advantages. While the sector faces supply complexities—often tied to its status as a by-product of acrylonitrile production—major players like INEOS AG are pivoting toward sustainable, bio-based manufacturing to mitigate environmental impact and meet stringent global regulations.